Trial Outcomes & Findings for Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis (NCT NCT04529980)

NCT ID: NCT04529980

Last Updated: 2024-08-13

Results Overview

Length of hospital stay measured in hours from admission to discharge. from admission to discharge, up to 1 month

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

98 participants

Primary outcome timeframe

From admission to discharge, up to 1 month

Results posted on

2024-08-13

Participant Flow

Participant milestones

Participant milestones
Measure
Lactobacillus Rhanmosus GG(LGG®) Group
Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge. Lactobacillus rhamnosus GG (LGG) Probiotic: Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
Placebo Control Group
Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge. Placebo: Placebo
Overall Study
STARTED
57
41
Overall Study
COMPLETED
53
40
Overall Study
NOT COMPLETED
4
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lactobacillus Rhanmosus GG(LGG®) Group
n=53 Participants
Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge. Lactobacillus rhamnosus GG (LGG) Probiotic: Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
Placebo Control Group
n=40 Participants
Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge. Placebo: Placebo
Total
n=93 Participants
Total of all reporting groups
Age, Categorical
<=18 years
53 Participants
n=5 Participants
40 Participants
n=7 Participants
93 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Continuous
10.23 years
STANDARD_DEVIATION 3.51 • n=5 Participants
10.53 years
STANDARD_DEVIATION 3.94 • n=7 Participants
10.29 years
STANDARD_DEVIATION 3.65 • n=5 Participants
Sex: Female, Male
Female
20 Participants
n=5 Participants
23 Participants
n=7 Participants
43 Participants
n=5 Participants
Sex: Female, Male
Male
33 Participants
n=5 Participants
17 Participants
n=7 Participants
50 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
36 Participants
n=5 Participants
29 Participants
n=7 Participants
65 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants
n=5 Participants
11 Participants
n=7 Participants
27 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
3 Participants
n=5 Participants
0 Participants
n=7 Participants
3 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=5 Participants
2 Participants
n=7 Participants
6 Participants
n=5 Participants
Race (NIH/OMB)
White
45 Participants
n=5 Participants
38 Participants
n=7 Participants
83 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Region of Enrollment
United States
53 Participants
n=5 Participants
40 Participants
n=7 Participants
93 Participants
n=5 Participants

PRIMARY outcome

Timeframe: From admission to discharge, up to 1 month

Length of hospital stay measured in hours from admission to discharge. from admission to discharge, up to 1 month

Outcome measures

Outcome measures
Measure
Lactobacillus Rhanmosus GG(LGG®) Group
n=53 Participants
Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge. Lactobacillus rhamnosus GG (LGG) Probiotic: Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
Placebo Control Group
n=40 Participants
Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge. Placebo: Placebo
Length of Hospital Stay
121.55 hours
Standard Deviation 59.21
131.69 hours
Standard Deviation 74.27

SECONDARY outcome

Timeframe: up to 1 month

Documented number of diarrhea episodes each day in EHR.

Outcome measures

Outcome measures
Measure
Lactobacillus Rhanmosus GG(LGG®) Group
n=53 Participants
Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge. Lactobacillus rhamnosus GG (LGG) Probiotic: Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
Placebo Control Group
n=40 Participants
Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge. Placebo: Placebo
Number of Diarrhea Episodes Daily
12.43 episodes/day
Standard Deviation 15.51
9.50 episodes/day
Standard Deviation 11.05

Adverse Events

Lactobacillus Rhanmosus GG(LGG®) Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Mayra Garcia, DNP, APRN, PCNS-BC, EBP-C

Children's Health Children's Medical Center

Phone: 12144567990

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place